MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
Healthcare
$1.28 +3.98%
+$0.05 today
- Market cap
- $132.16M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
52W Low $0.64High $2.37
Volume 1.67M
Average 0.95M
Income Statement
Follow revenue through to earnings.
Revenue
$33.03M
FY 2025 · Annual
-14.5% YoYOperating Income
-$45.28M
FY 2025 · Annual
Net Income
-$44.63M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Cost of Revenue | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| Gross Profit | 30.25M | 39.16M | 36.55M | 31.53M | 26.8M |
| Gross Margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Research & Development | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| Selling, General & Admin | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| Operating Expenses | 48.44M | 66.52M | 84.85M | 82.72M | 72.09M |
| Depreciation & Amortization | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M |
| EBITDA | (16.61M) | (20.75M) | (33.75M) | (36.27M) | (39.49M) |
| EBITDA Margin | -49.0% | -46.9% | -81.7% | -93.9% | -119.6% |
| Operating Income | (18.19M) | (27.36M) | (48.3M) | (51.2M) | (45.29M) |
| Operating Margin | -53.7% | -61.8% | -117.0% | -132.5% | -137.1% |
| Interest Income | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income / Expenses | (893.6K) | 3.79M | 10.38M | 10.14M | 655K |
| Income Before Tax | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Pre-Tax Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Net Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (Basic) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| EPS (Diluted) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| 90.62M | 101.7M | 103.27M | 104.85M | 106.43M | |
| 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
MXCT Earnings Waterfall · TTM
NASDAQ:MXCT · Revenue to Net Income
Key Ratios
EPS$-0.37
Gross Margin81.4%
Net Margin-126.9%
P/E Ratio-4.1
P/S Ratio20.6
Analysis
$32.3M of revenue converted into -$39.1M of net income for the selected period. Gross margin is 81.4% and net margin is -126.9%, showing how much revenue survives after costs and taxes. EPS is $-0.37, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13D | SC 13D filing | Nov 2, 2026 | |
| SC 13D | SC 13D filing | Oct 15, 2026 | |
| 8-K | Current report | Oct 14, 2026 |
How much revenue does MXCT generate?
MaxCyte, Inc. (MXCT) reported $33.03M of revenue in fiscal 2025.
Is MXCT profitable?
MaxCyte, Inc. (MXCT) reported -$44.63M of net income, with a net margin of -135.1%.
Continue the stock analysis
Jump to another research area for this company.